ArticleMethods in enzymology2026
Site-specific antibody labeling via endo-S2 mediated Fc glycan remodeling.
Article in Methods in enzymology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
Abstract
Site-specific labeling of antibodies is highly valuable for diagnostic and therapeutic applications. The chemoenzymatic Fc glycan remodeling method provides a platform for site-specific antibody functionalization without perturbing antigen recognition. In this chapter, we describe a one-pot enzymatic method to produce fluorophore- and biotin-labeled antibodies using S. pyogenes endoglycosidase S2 (Endo-S2) as the enzyme and functionalized disaccharide oxazolines as the substrate. This method enables the efficient installation of azide, biotin, or fluorophore functionalities at the Fc glycosylation site, yielding homogeneous antibody conjugates. Trastuzumab, a therapeutic monoclonal antibody, was chosen as the model antibody for this protocol but the platform should also be applicable for other recombinant IgG antibodies. This protocol offers a robust and modular approach for preparing site-specifically labeled antibodies for various applications.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.